Dr. Brown on the Use of PARP Inhibitors in the Upfront and Recurrent Settings in Ovarian Cancer
March 17th 2023
Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.